GLP-1 drugs linked to 41% lower obesity-related cancer risk

A new study published in Annals of Oncology analyzed health data from more than 229,000 obese, non-diabetic individuals and found a striking link between GLP-1 medications and reduced cancer risk.

41% overall reduction in obesity-related cancers

Participants who took GLP-1 medications containing semaglutide or tirzepatide saw a 41% decrease in their overall risk of developing an obesity-related cancer. Researchers noted this is a signal large enough to drive clinical guidelines if confirmed in prospective trials.

Four cancers saw 50% or greater risk reduction

The most dramatic drops occurred in endometrial cancer (58% lower risk), pancreatic cancer, colorectal cancer, and multiple myeloma — all with reductions of 50% or more. Endometrial cancer is rising fastest in younger women and tightly linked to obesity, making this finding especially significant.

Why GLP-1s may protect beyond weight loss

Researchers believe the effect is more than just shedding pounds. GLP-1 receptors are expressed directly on certain cancer cells, suggesting the drug may act on tumors themselves. Weight loss still matters — excess fat promotes chronic inflammation and insulin resistance — but the biology appears to run deeper.

What this means for members

For people already using tirzepatide or semaglutide for weight management, this study adds a potentially major long-term benefit to the column. While more research is needed to prove causation, the scale of the signal across a quarter-million patients is hard to ignore.